DEF: Glucotrack Seeks Stockholder Approval for Reverse Stock Split and Equity Incentive Plan Amendment

Glucotrack is asking stockholders to approve a reverse stock split, elect directors, ratify the appointment of its accounting firm, and amend its equity incentive plan at the upcoming annual meeting.

Summary

• Glucotrack, Inc. is holding its 2025 Annual Meeting of Stockholders on May 22, 2025.
• The meeting will be held virtually.
• Stockholders will vote on the election of five directors, ratification of the independent accounting firm, approval of a reverse stock split, and an amendment to the 2024 Equity Incentive Plan.
• The proposed reverse stock split would allow management to combine outstanding shares at a ratio not to exceed one-for-one hundred.
• The amendment to the 2024 Equity Incentive Plan would increase the number of shares available for issuance to 7,500,000.
• The record date for determining stockholders eligible to vote is April 21, 2025.
• As of the record date, there were 25,585,853 shares of Common Stock issued and outstanding.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily conveying information about upcoming votes and corporate governance matters. The need for a reverse stock split suggests some financial challenges, but the focus is on addressing those challenges.

Positives

• The proposed reverse stock split aims to maintain the company's listing on The Nasdaq Capital Market and regain compliance with the Bid Price Rule.
• The increased market price of the Common Stock expected as a result of implementing the Reverse Stock Split could improve the marketability and liquidity of the Common Stock and may encourage interest and trading in the Common Stock.
• The amendment to the 2024 Equity Incentive Plan is intended to attract, retain, and motivate key personnel through stock-based long-term incentive compensation.

Negatives

• The company received a notice from Nasdaq stating that it was no longer in compliance with the Bid Price Rule on December 31, 2024.
• The company has a compliance period until June 30, 2025, to regain compliance with the Bid Price Rule.
• The proposed Reverse Stock Split may decrease the liquidity of our Common Stock.

Risks

• The proposed Reverse Stock Split may not increase the price of the common stock and have the desired effect of maintaining compliance with Nasdaqs Bid Price Rule.
• The market price per post-Reverse Stock Split share may not exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time.
• The company may be delisted due to a failure to meet other continued listing requirements, including Nasdaq requirements related to the minimum stockholders equity, minimum number of shares that must be in the public float and the minimum market value of the public float.

Future Outlook

The company aims to regain compliance with Nasdaq's Bid Price Rule by June 30, 2025, and maintain its listing on The Nasdaq Capital Market.

Industry Context

Reverse stock splits are often used by companies facing delisting from major exchanges to increase their stock price and regain compliance with listing requirements. Equity incentive plans are a common tool for attracting and retaining talent in competitive industries.

Comparison to Industry Standards

• Reverse stock splits are a relatively common strategy for companies facing delisting, although their success in the long term varies.
• Companies like DryShips Inc. have used reverse stock splits repeatedly to maintain listing compliance, while others have ultimately been delisted despite the strategy.
• The size of the proposed equity incentive plan, with 7,500,000 shares, should be compared to similar companies in the medical device industry to assess its competitiveness.

Related Party Transactions

• On October 7, 2022, the Company entered into the Intellectual Property Purchase Agreement (the IP Purchase Agreement) with Paul Goode, which is the Company's Chief Executive Officer, pursuant to which Dr. Goode sold, assigned, transferred, conveyed and delivered to the Company, all of his right, title and interest in and to the following assets, properties and rights (collectively, the Purchased Assets): (a) all rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the Conveyed Intellectual Property); and (b) all the goodwill relating to the Purchased Assets.
• On April 22, 2024, the Company entered into a private placement agreement under which the Company issued 3,969 shares of its Common Stock at a price of $126.0 per share for aggregate gross proceeds of $500.
• On June 27, 2024, the Company entered into note and warrant purchase agreements with certain officers, directors, and existing investors (the June 27 Investors), providing for the private placement of unsecured promissory notes in the aggregate principal amount of $100,000 (the June 27 Notes) and warrants (the June 27 Warrants) to purchase up to an aggregate of 15,000 shares of Common Stock.
• On July 18, 2024, the Company entered into a series of convertible promissory notes with certain officers and directors (the July 18 Investors), providing for the private placement of unsecured convertible promissory notes in the aggregate principal amount of $360,000 (the July 18 Notes and each a July 18 Note).
• On July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the July 30 Warrants) with an existing investor (the July 30 Holder), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of 4,000,000 (the July 30 Note).
• In a private placement offering completed concurrently with the November 2024 Offering (the Concurrent Private Offering), the July 30 Holder, which is an existing investor controlled by a director of the Company, converted approximately $4,093,112 of debt, which represented the then outstanding principal and accrued interest under the July 30 Note (the July 30 Note Debt).
• In addition, concurrently with the November 2024 Offering, the Company converted on substantially the same terms as the November Offering, the three outstanding July 18 Notes, with an aggregate outstanding principal and accrued interest in the amount of $304,494.
• On March 11, 2025, the July 30 Holder and the July 18 Investors, exchanged their Series B Common Warrants pursuant to exchange notices, requiring the delivery of an aggregate of 2,749,817 shares of Common Stock.
• On April 14, 2025, Dr. Victoria Carr-Brendel, a director nominee, through her consulting company, VCarrbrendel, LLC (the Contractor), entered into a contracting agreement with the Company, pursuant to which, the Contractor will assist with business development (the Services).

Stakeholder Impact

• Shareholders will be impacted by the potential reverse stock split and its effect on the stock price and trading liquidity.
• Employees, consultants, and directors may be affected by the amendment to the equity incentive plan.
• The company's ability to maintain its Nasdaq listing is important for investor confidence and access to capital.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on May 22, 2025.
• Management will determine whether to implement the reverse stock split and at what ratio, if approved by stockholders.
• The company will continue to work towards regaining compliance with Nasdaq's Bid Price Rule.

Key Dates

Keywords

reverse stock split, equity incentive plan, proxy statement, annual meeting, directors, Nasdaq, common stock, stockholders, governance, compensation